MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
Article 223-16 of the General Regulations of the Financial Markets Authority
(AMF - Autorité des Marchés Financiers)
LYON, France, May 06, 2024--(BUSINESS WIRE)--Regulatory News:
MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies™ (MET) dedicated to enhancing survival of patients with cancer, today published the number of shares comprising the share capital and the total number of voting rights (Article L. 233-8 of the French Commercial Code (Code de commerce) and Article 223-16 of the General Regulations of French Autorité des Marchés Financiers (AMF)) on April 30, 2024.
Listing place: Euronext Paris
ISIN code: FR0012634822
Website: www.maatpharma.com
Date | Total number of shares | Total number of | Total number of |
04/30/2024 | 11 623 653 | 11 623 653 | 11 602 636 |
(1) In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended. |
(2) Effective voting rights correspond to the total number of voting rights that may be used at a General Meeting. The total number of effective voting rights is calculated without taking into account the shares with suspended voting rights. |
About MaaT Pharma
MaaT Pharma, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, MaaT Pharma has launched, in March 2022, an open-label, single arm Phase 3 clinical trial in patients with acute GvHD, following the achievement of its proof of concept in a Phase 2 trial. Its powerful discovery and analysis platform, gutPrint®, enables the identification of novel disease targets, evaluation of drug candidates, and identification of biomarkers for microbiome-related conditions. The company’s Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice. MaaT Pharma is listed on Euronext Paris (ticker: MAAT).
View source version on businesswire.com: https://www.businesswire.com/news/home/20240506732977/en/
Contacts
MaaT Pharma – Investor Relations
Guilhaume DEBROAS, Ph.D.
Head of Investor Relations
+33 6 16 48 92 50
invest@maat-pharma.com
MaaT Pharma – Media Relations
Pauline RICHAUD
Senior PR & Corporate Communications Manager
+33 6 14 06 45 92
media@maat-pharma.com
Trophic Communications
Jacob VERGHESE or
Priscillia PERRIN
+49 151 7441 6179
maat@trophic.eu